These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16636750)

  • 1. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.
    Levin VA; Phuphanich S; Yung WK; Forsyth PA; Maestro RD; Perry JR; Fuller GN; Baillet M
    J Neurooncol; 2006 Jul; 78(3):295-302. PubMed ID: 16636750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects.
    King J; Zhao J; Clingan P; Morris D
    Anticancer Res; 2003; 23(1B):639-45. PubMed ID: 12680160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial.
    Bramhall SR; Hallissey MT; Whiting J; Scholefield J; Tierney G; Stuart RC; Hawkins RE; McCulloch P; Maughan T; Brown PD; Baillet M; Fielding JW
    Br J Cancer; 2002 Jun; 86(12):1864-70. PubMed ID: 12085177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.
    Shepherd FA; Giaccone G; Seymour L; Debruyne C; Bezjak A; Hirsh V; Smylie M; Rubin S; Martins H; Lamont A; Krzakowski M; Sadura A; Zee B
    J Clin Oncol; 2002 Nov; 20(22):4434-9. PubMed ID: 12431965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
    Groves MD; Puduvalli VK; Conrad CA; Gilbert MR; Yung WK; Jaeckle K; Liu V; Hess KR; Aldape KD; Levin VA
    J Neurooncol; 2006 Oct; 80(1):83-90. PubMed ID: 16639492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study.
    Krzeski P; Buckland-Wright C; Bálint G; Cline GA; Stoner K; Lyon R; Beary J; Aronstein WS; Spector TD
    Arthritis Res Ther; 2007; 9(5):R109. PubMed ID: 17958901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
    Groves MD; Puduvalli VK; Hess KR; Jaeckle KA; Peterson P; Yung WK; Levin VA
    J Clin Oncol; 2002 Mar; 20(5):1383-8. PubMed ID: 11870183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196.
    Zucker S; Wang M; Sparano JA; Gradishar WJ; Ingle JN; Davidson NE;
    Clin Breast Cancer; 2006 Feb; 6(6):525-9. PubMed ID: 16595036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
    Sotelo J; Briceño E; López-González MA
    Ann Intern Med; 2006 Mar; 144(5):337-43. PubMed ID: 16520474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
    Chinot OL; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Carpentier AF; Hoang-Xuan K; Kavan P; Cernea D; Brandes AA; Hilton M; Abrey L; Cloughesy T
    N Engl J Med; 2014 Feb; 370(8):709-22. PubMed ID: 24552318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196.
    Sparano JA; Bernardo P; Stephenson P; Gradishar WJ; Ingle JN; Zucker S; Davidson NE
    J Clin Oncol; 2004 Dec; 22(23):4683-90. PubMed ID: 15570070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
    Rosenbaum E; Zahurak M; Sinibaldi V; Carducci MA; Pili R; Laufer M; DeWeese TL; Eisenberger MA
    Clin Cancer Res; 2005 Jun; 11(12):4437-43. PubMed ID: 15958628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma.
    Gabelloni P; Da Pozzo E; Bendinelli S; Costa B; Nuti E; Casalini F; Orlandini E; Da Settimo F; Rossello A; Martini C
    Neuroscience; 2010 Jun; 168(2):514-22. PubMed ID: 20382206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marimastat in patients with advanced pancreatic cancer: a dose-finding study.
    Rosemurgy A; Harris J; Langleben A; Casper E; Goode S; Rasmussen H
    Am J Clin Oncol; 1999 Jun; 22(3):247-52. PubMed ID: 10362330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
    Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
    Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen.
    Primrose JN; Bleiberg H; Daniel F; Van Belle S; Mansi JL; Seymour M; Johnson PW; Neoptolemos JP; Baillet M; Barker K; Berrington A; Brown PD; Millar AW; Lynch KP
    Br J Cancer; 1999 Feb; 79(3-4):509-14. PubMed ID: 10027321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.
    Wojtowicz-Praga S; Torri J; Johnson M; Steen V; Marshall J; Ness E; Dickson R; Sale M; Rasmussen HS; Chiodo TA; Hawkins MJ
    J Clin Oncol; 1998 Jun; 16(6):2150-6. PubMed ID: 9626215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults.
    Gross MW; Altscher R; Brandtner M; Haeusser-Mischlich H; Chiricuta IC; Siegmann AD; Engenhart-Cabillic R
    Clin Neurol Neurosurg; 2005 Apr; 107(3):207-13. PubMed ID: 15823676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
    Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.